Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5 Mln
Revenue (TTM)
$14 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.1
Industry P/E
--
EV/EBITDA
-0.2
Div. Yield
0 %
Debt to Equity
--
Book Value
$2.7
EPS
$-2.1
Face value
--
Shares outstanding
1,615,760
CFO
$-71.02 Mln
EBITDA
$-81.84 Mln
Net Profit
$-49.28 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sonoma Pharmaceuticals (SNOA)
| 9.3 | -11.4 | -15.5 | -27.1 | -63.6 | -54.2 | -45.9 |
|
BSE Sensex
| 4.7 | 1.2 | 6.5 | 6.1 | 16.5 | 18.6 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Sonoma Pharmaceuticals (SNOA)
| -25.1 | -83.9 | -75.4 | -37.2 | 66.5 | -32.0 | -86.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sonoma Pharmaceuticals (SNOA)
|
2.9 | 4.9 | 14.3 | -3.5 | -21.4 | -65.5 | -- | 1.1 |
| 17.9 | 4,328.3 | 459.4 | 206.8 | 25.6 | 68.3 | 21.6 | 11.3 | |
| 7.9 | 3,640.5 | 2,830.2 | -13.1 | 11.5 | -- | -- | 86.1 | |
| 101.7 | 5,065.9 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 95.2 | |
| 54.1 | 10,547.7 | 2,937.8 | 523.9 | 23.2 | 9.3 | 20.4 | 1.9 | |
| 42.2 | 7,923.7 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 74.3 | 7,569.5 | 685.5 | 132.9 | 15.6 | 20.1 | 62.1 | 11.1 | |
| 13.4 | 6,684.9 | 4,427.0 | 373.0 | -0.7 | 5.8 | 17.9 | 1.0 | |
| 84.4 | 4,123.2 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.4 | 2.3 | |
| 8.9 | 10,410.5 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin... America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado. Read more
CEO, President & Director
Ms. Amy M. Trombly
CEO, President & Director
Ms. Amy M. Trombly
Headquarters
Boulder, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sonoma Pharmaceuticals Inc (SNOA) stood at -- as on 31-Mar-25
The share price of Sonoma Pharmaceuticals Inc (SNOA) is $2.94 (NASDAQ) as of 23-Jun-2025 16:00 EDT. Sonoma Pharmaceuticals Inc (SNOA) has given a return of -63.61% in the last 3 years.
Sonoma Pharmaceuticals Inc (SNOA) has a market capitalisation of $ 5 Mln as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Sonoma Pharmaceuticals Inc (SNOA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sonoma Pharmaceuticals Inc (SNOA) and enter the required number of quantities and click on buy to purchase the shares of Sonoma Pharmaceuticals Inc (SNOA).
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
The CEO & director of Ms. Amy M. Trombly. is Sonoma Pharmaceuticals Inc (SNOA), and CFO & Sr. VP is Ms. Amy M. Trombly.
There is no promoter pledging in Sonoma Pharmaceuticals Inc (SNOA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,059
|
|
|
1,029
|
|
|
762
|
|
|
761
|
|
|
676
|
|
|
507
|
|
|
433
|
|
|
414
|
|
|
368
|
| Sonoma Pharmaceuticals Inc. (SNOA) | Ratios |
|---|---|
|
Return on equity(%)
|
-65.55
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-24.2
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Sonoma Pharmaceuticals Inc (SNOA) was $0 Mln.
$-0.10
(
